Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the use of Finastopic, a carrier for finasteride solutions by Isdin, and compares it to a standard propylene glycol (PG) solution. The user was prescribed a 1% finasteride solution using Finastopic and has been using a self-compounded 0.025% topical finasteride with minoxidil.

People are discussing the use of an untested hair loss treatment called PP405, which is not available on the grey market. Some users are trying a mimic formulation called HP3, reporting thicker hair but no new growth yet.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

A user is making a homemade topical finasteride solution by dissolving crushed finasteride tablets in ethanol and PG. They are unsure if the final solution maintains the intended concentration after filtering and are considering adding more ethanol to ensure accuracy.

The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.

A compound called MTP3 from the Monoterpene family was found to be safe and highly effective at treating hair loss by inhibiting the FGF5 gene, but its identity is undisclosed for commercial reasons. No specific treatments like Minoxidil, finasteride, or RU58841 were discussed.

The conversation is about using a dermastamp for hair loss treatment and concerns about a potentially scam product, pp405. It suggests sticking with known treatments like finasteride and minoxidil.

PP405 is discussed as a potential hair growth stimulant, possibly more effective than minoxidil, but not a cure for hair loss. There is skepticism about its ability to regrow "deadzones," and concerns about its impact on those with hair transplants.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

PP405 may not need daily use like minoxidil, but finasteride might still be needed to maintain hair regrowth. PP405 reawakens dormant hair follicles, potentially offering a long-term solution, though not a permanent cure.

PP405 may revive dormant hair follicles, and DHT blockers like finasteride or dutasteride could maintain new hair. Combining PP405 with minoxidil might be optimal, but long-term effects and continuous use are uncertain.

PP405 is a new drug in Phase 2 trials for hair loss, generating cautious optimism among users. Some users are currently using finasteride and experiencing side effects, while others are skeptical about unapproved products being sold.

Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.

Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.

The conversation discusses the use of ethanol and propylene glycol (PG) in topical solutions for hair loss treatments, specifically Minoxidil. The user dislikes the texture of PG and questions the ideal ratio and necessity of PG in these solutions.

The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It jokingly suggests the creation of a new chemical called RU99999.

The conversation discusses adjusting the isopropyl alcohol, propylene glycol, and water ratios in a topical finasteride solution for better scalp comfort and less dandruff. The user considers using 20ml IPA, 25ml PG, and 15ml water in a 60ml bottle, moving away from mixing finasteride with topical minoxidil.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

Avoid home-compounding topical minoxidil due to potential risks and complications. Use proper equipment and techniques to prevent aerosolization and ensure effective dissolution.

A user is using oral finasteride, oral dutasteride, and drinking topical minoxidil for hair loss, despite health warnings. Switching from finasteride to dutasteride did not improve hair density.

The user experienced significant hair regrowth using 1mg oral finasteride, DIM, and beetroot powder, while also focusing on gut health and reducing alcohol intake. Other users discussed the importance of iodine, fermented foods, and maintaining a balanced diet for overall health and hair improvement.

Hair loss treatments like olive oil, coconut oil, and finasteride are discussed with skepticism and humor. The conversation highlights disbelief in quick fixes and the ongoing search for effective solutions.

Hair fibers can effectively cover thinning hair when used with minoxidil and hairspray but require daily application and can be inconvenient in certain conditions. Some users prefer treatments like finasteride, dutasteride, microneedling, or wigs due to the maintenance and limitations of hair fibers.

The conversation discusses skepticism about the effectiveness of scalp tension theory and scalp massagers for hair regrowth, contrasting it with treatments like finasteride and minoxidil, which have more user-reported results. Participants question the belief in scalp tension theory, suggesting it may be a marketing tactic, while others argue for a multifactorial approach to hair loss.

The user regrets stopping finasteride and minoxidil due to side effects but plans to resume treatment. They consider using finasteride every other day and continuing topical minoxidil to manage side effects while maintaining hair.

Non-steroidal ways to reduce scalp inflammation include using topical melatonin, urea shampoo, Zyrtec, turmeric with black pepper, omega-3 supplements, a self-made topical solution with cetirizine, melatonin, and piroctone olamine, ketoconazole shampoo, witch hazel shampoo, tacrolimus, and lifestyle changes like a healthy diet and regular exercise. Some users also mentioned unconventional methods like infrared light therapy and a carnivore diet.

The FDA warned that topical finasteride can cause serious side effects like sexual dysfunction and brain fog, similar to oral finasteride. Compounded topical formulations pose additional risks due to lack of regulation.

A product that makes hair look thicker and healthier without promoting regrowth. Discussions include treatments like minoxidil, finasteride, red light therapy, and a serum with caffeine and peptides, with mixed effectiveness opinions.

Increased Malassezia and Cutibacterium in the scalp microbiome are linked to higher sebum production and inflammation in androgenetic alopecia (AGA). Treatments include ciclopirox shampoo, benzoyl peroxide shampoo, clobetasol propionate, calcipotriol, minoxidil, finasteride, and dutasteride.

The user plans to lower their oral minoxidil dose from 5 mg to 2.5 mg to reduce side effects like puffiness and hypertrichosis, while also using finasteride and accutane. They are considering caffeine serums for puffiness and discussing dietary changes or switching to topical minoxidil to address bloating.